Drugs / NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy）
NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy）
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03462316 | May 2018 → Apr 2020 | bone sarcoma, soft tissue sarcoma | Sun Yat-sen University | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy） | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03462316 ↗ |